Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials

References

• DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5.
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–4434.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–1948.
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J clin oncol. 2008;26:1275–1281.
   PubMed Web of Science ®Google Scholar
• Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19:5533–5540.
   PubMed Web of Science ®Google Scholar
• Mylavarapu S, Das A, Roy M. Role of BRCA mutations in the modulation of response to platinum therapy. Front Oncol. 2018;8:16.
   PubMed Web of Science ®Google Scholar
• Tazzite A, Jouhadi H, Benider A, et al. BRCA mutational status is a promising predictive biomarker for platinum-based chemotherapy in triple-negative breast cancer. Curr Drug Targets. 2020;21:962–973.
   PubMed Web of Science ®Google Scholar
• Vernieri C, Prisciandaro M, Milano M, et al. Single-agent gemcitabine vs. carboplatin-gemcitabine in advanced breast cancer: a retrospective comparison of efficacy and safety profiles. Clin Breast Cancer. 2019;19:e306–e18.
   PubMed Web of Science ®Google Scholar
• Vetter M, Fokas S, Biskup E, et al. Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience. Oncotarget. 2017;8(43):75617–75626.
   PubMedGoogle Scholar
• Zhang P, Yin Y, Mo H, et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget. 2016;7(37):60647–60656.
   PubMedGoogle Scholar
• Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of Veliparib–Carboplatin treatment in breast cancer. N Engl J Med. 2016;375(1):23–34.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yao L, Liu Y, et al. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer. Int J Cancer. 2021;148(4): 941–949.
   PubMed Web of Science ®Google Scholar
• Du F, Wang W, Wang Y, et al. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. Breast Cancer Res Treat. 2020;182:67–77.
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Mobus V, Tesch H, et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. Eur J Cancer. 2019;106:181–192.
   PubMed Web of Science ®Google Scholar
• Wu X, Tang P, Li S, et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nat Commun. 2018;9:832.
   PubMed Web of Science ®Google Scholar
• Su YW, Hung CY, Lam HB, et al. A single institution experience of incorporation of cisplatin into adjuvant chemotherapy for patients with triple-negative breast cancer of unknown BRCA mutation status. Clin Med Insights Oncol. 2018;12:1179554918794672.
   Web of Science ®Google Scholar
• Sella T, Gal Yam EN, Levanon K, et al. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort. Vol. 40. Scotland): Breast (Edinburgh; 2018. p. 141–146.
   Google Scholar
• Loibl S, Weber KE, Timms KM, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018;29:2341–2347.
   PubMed Web of Science ®Google Scholar
• Gluz O, Nitz U, Liedtke C, et al. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. J Natl Cancer Inst. 2018;110:628–637.
   PubMedGoogle Scholar
• Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13–21.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15:747–756.
   PubMed Web of Science ®Google Scholar
• Ando M, Yamauchi H, Aogi K, et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Res Treat. 2014;145:401–409.
   PubMed Web of Science ®Google Scholar
• Alba E, Chacon JI, Lluch A, et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat. 2012;136:487–493.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu ZY, Li J, et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label phase II trial. Int J Cancer. 2022;150:654–662.
   PubMed Web of Science ®Google Scholar
• Yan W, Wu X, Wang S, et al. Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial. Ther Adv Med Oncol. 2022;14:17588359221107111.
   Web of Science ®Google Scholar
• Mayer IA, Zhao F, Arteaga CL, et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative Breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021;39:2539–2551.
   PubMed Web of Science ®Google Scholar
• Pohl-Rescigno E, Hauke J, Loibl S, et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary Analysis of the GeparOcto randomized clinical trial. JAMA Oncol. 2020;6:744–748.
   PubMed Web of Science ®Google Scholar
• Gazinska P, Grigoriadis A, Brown JP, et al. Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. Mod Pathol. 2013;26:955–966.
   PubMed Web of Science ®Google Scholar
• Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16:1–11.
   PubMed Web of Science ®Google Scholar
• Schneider BP, Winer EP, Foulkes WD, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14:8010–8018.
   PubMed Web of Science ®Google Scholar
• Lara‐Medina F, Pérez‐Sánchez V, Saavedra‐Pérez D, et al. Triple‐negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011;117:3658–3669.
   PubMed Web of Science ®Google Scholar
• Xiu M, Zhang P, Wang X, et al. Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: a prospective cohort study with propensity-matched analysis. Int J Cancer. 2022;151:578–589.
   PubMed Web of Science ®Google Scholar
• Okines A, Turner N. Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer. Ann Oncol. 2022;33:657–658.
   PubMed Web of Science ®Google Scholar
• Geyer CE, Sikov WM, Huober J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022;33:384–394.
   PubMed Web of Science ®Google Scholar
• Børresen‐Dale AL. TP53 and breast cancer. Hum Mutat. 2003;21:292–300.
   PubMed Web of Science ®Google Scholar
• Ratanaphan A. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci. 2012;13:14898–14916.
   PubMed Web of Science ®Google Scholar
• Papageorgis P, Ozturk S, Lambert AW, et al. Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis. Breast Cancer Res. 2015;17:98.
   PubMed Web of Science ®Google Scholar
• Leong C-O, Vidnovic N, DeYoung MP, et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest. 2007;117:1370–1380.
   PubMed Web of Science ®Google Scholar
• Rocca A, Viale G, Gelber RD, et al. Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemother Pharmacol. 2008;61:965–971.
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, He L, Mayer EL, et al. Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): correlative studies from TBCRC009. Am Soc Clin Oncol. 2014;32:1020–1020.
   PubMed Web of Science ®Google Scholar
• McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res. 2006;66:8109–8115.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Jnci. 2003;95:1482–1485.
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11:5175–5180.
   PubMed Web of Science ®Google Scholar
• Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J clin oncol. 2006;24:5652–5657.
   PubMed Web of Science ®Google Scholar
• de Ruijter TC, Veeck J, de Hoon JP, et al. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137:183–192.
   PubMed Web of Science ®Google Scholar
• Byrski T, Dent R, Blecharz P, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res. 2012;14:R110.
   PubMed Web of Science ®Google Scholar
• Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115:359–363.
   PubMed Web of Science ®Google Scholar